Sentence examples for clinically effectiveness from inspiring English sources

The justification for this may be found in the abundance of reports of clinically effectiveness interventions that have little hope of being implemented in real healthcare settings.

Many of the agents have been used in preclinical, phase I or phase II trials; few trials are in phase III or IV, but their clinically effectiveness remains to be established.

Although it remains unclear whether or not the modulating effects of cimetidine on DC function observed in our investigation in vitro have clinically substantial meanings, clinical effectiveness of cimetidine against gastrointestinal malignancies are considered to be due to the total of immunological and non-immunological actions of cimetidine.

Therefore, the present study confirmed the anxiolytic-like effect of a FAT-M using two validated experimental animal models currently used to test the effectiveness of clinically effective anxiolytics, the defensive burying test [ 16] and elevated plus maze [ 17].

36 37 Our study attempted to fill this gap by evaluating the clinical effectiveness of warfarin treatment in clinically relevant subgroups.

However, insignificant differences do not allow concluding that interval or continuous are of clinically equivalent effectiveness[ 13] These trials were too small to show clinical equivalence or non-inferiority and they did not provide evidence on the tolerance of these two exercise modalities.

The combination of memantine and donepezil has been shown to be "of statistically significant but clinically marginal effectiveness".

The alternative hypothesis is that interval exercise is not of clinically inferior effectiveness compared with high intensity continuous exercise.

Our null hypothesis is that high intensity continuous exercise is of clinically superior effectiveness compared with interval exercise to improve HRQL (δ ≥ 0.5 in CRQ domains scores).

Studies conducted on tumor tissue models attest to the clinically satisfactory effectiveness of drugs that slow down lymphangiogenesis by inhibiting VEGF-R3, the receptor that is the most specific to lymphangiogenesis [ 31, 34].

The limitations were that we need clinically relevant cost-effectiveness studies, probably at the country level, and a large debate involving public health organizations and pharmaceuticals companies, but also clinicians and patients, to challenge the rising of the cancer patient's management costs.